Prometheus® European liver disease outcome study
Completed
- Conditions
- Severe deterioration of chronic liver disease.Urological and Genital DiseasesLiver disease
- Registration Number
- ISRCTN50777531
- Lead Sponsor
- Fresenius Medical Care (Germany)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 200
Inclusion Criteria
Patients with severe deterioration of chronic liver disease.
Exclusion Criteria
Conditions strongly interfering with the study outcome (e.g. active HCC, extrahepatic malignancy).
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Patient survival.
- Secondary Outcome Measures
Name Time Method Clinical course of the patient (e.g. length of stay in intensive care/in hospital, number of hospital re-admissions, liver transplantation status, laboratory parameters).
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie severe chronic liver disease deterioration in the Prometheus® trial sponsored by Fresenius Medical Care?
How does the Prometheus® intervention compare to standard-of-care therapies for advanced liver disease outcomes in Europe?
Which biomarkers are associated with patient selection and treatment response prediction in the Prometheus® liver disease study?
What adverse events were reported in the Prometheus® trial for severe liver disease, and what management strategies were employed?
What related compounds or combination therapies are being evaluated alongside Prometheus® for chronic liver disease by Fresenius Medical Care?